Dr. Reddy’s (NYSE: RDY) marks 25 years on NYSE with Closing Bell ceremony
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories Ltd. filed a Form 6-K to share a press release announcing that it has been invited to ring the Closing Bell® at the New York Stock Exchange to celebrate 25 years of its NYSE listing.
The ceremony will be held at the NYSE headquarters in New York City on May 29, 2026 at 4:00 pm EDT, and will be livestreamed on NYSE.com and the New York Stock Exchange YouTube channel. Senior management, independent directors, former directors and other officials of Dr. Reddy’s are expected to attend.
The company highlights its long-standing focus on affordable and innovative medicines, its global presence across key markets such as the USA, India, Russia & CIS, China, Brazil and Europe, and its early adoption of sustainability and ESG goals.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Closing Bell® financial
forward-looking statements regulatory
ESG financial
Regulation 30 regulatory
Sustainability Report financial
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Number |
| Description of Exhibits |
|
|
|
99.1 | Intimation dated May 28, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
|
|
|
|
Date: May 28, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
May 28, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Please find enclosed a Press Release viz. “Dr. Reddy's Laboratories to Ring the Closing Bell® at the New York Stock Exchange.”
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | CONTACT | |
INVESTOR RELATIONS | MEDIA RELATIONS | |
AISHWARYA SITHARAM AISHWARYASITHARAM@DRREDDYS.COM | PRIYA K PRIYAK@DRREDDYS.COM | |
Dr. Reddy's Laboratories to Ring the Closing Bell® at the New York
Stock Exchange
· | The ceremony marks 25 years of Dr. Reddy’s listing on the New York Stock Exchange |
· | In April 2001, Dr. Reddy's became the first pharmaceutical company in Asia, outside Japan, to be listed on the New York Stock Exchange |
· | The Closing Bell® will be rung by Dr. Reddy’s senior management team, led by Chairman Satish Reddy |
HYDERABAD, INDIA, May 28, 2026 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced that it has been invited to ring the Closing Bell® at the New York Stock Exchange (NYSE), to celebrate 25 years of its listing on the NYSE. In April 2001, Dr. Reddy's became the first pharmaceutical company in Asia, outside Japan, to be listed on the NYSE.
The senior management team of Dr. Reddy’s, including Satish Reddy, Chairman; Erez Israeli, Chief Executive Officer; M.V. Ramana, Chief Executive Officer-Global Generics; M.V. Narasimham, Chief Financial Officer; Milan Kalawadia, Chief Executive Officer-North America; K Randhir Singh, HeadCompany Secretary & CSR, along with Arun M. Kumar (Independent Director), Penny Wan (Independent Director), Sridar Iyengar (former Independent Director), as well as other officials and invitees will attend the Closing Bell® ceremony at the NYSE headquarters, located in New York City, on May 29th, 2026 at 4.00 pm EDT (1.30 am IST on May 30th). The ceremony will be livestreamed on NYSE.com and New York Stock Exchange - YouTube.
Satish Reddy, Chairman, Dr. Reddy’s said: “Twenty-five years on the NYSE is more than a listing anniversary; it is a reaffirmation of our commitment to global governance, transparency, and innovation. When Dr. K. Anji Reddy founded this company, his vision was simple but powerful: bring affordable, innovative medicines to patients everywhere. That vision drove our NYSE debut in 2001 and continues to shape who we are today, a trusted name in the U.S. market, backed by differentiated products and consistent operations. This milestone belongs to our employees, our partners, and our shareholders. As we look ahead, we remain unwavering in our purpose: accelerating access to affordable and innovative healthcare, because Good Health Can't Wait."
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait,’ we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.
For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.